{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:53:00Z","timestamp":1791910380120,"version":"4.3.4"},"reference-count":75,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.vaccine.2026.129180","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:47:35Z","timestamp":1790869655000},"page":"129180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Summary of 2025 Society of Toxicology Workshop \u201cVaccine Toxicology in the Post-COVID Era\u201d"],"prefix":"10.1016","volume":"93","author":[{"given":"Sarah","family":"Gould","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia M.","family":"Rohde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Destexhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Tiesjema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129180_bb0075","author":"CPMP. Committee for Proprietary Medicinal Products"},{"key":"10.1016\/j.vaccine.2026.129180_bb0355","series-title":"Guidelines on the nonclinical evaluation of vaccine adjuvants and adjuvanted vaccines","author":"WHO. World Health Organization","year":"2014"},{"key":"10.1016\/j.vaccine.2026.129180_bb0350","series-title":"WHO guidelines on nonclinical evaluation of vaccines","author":"WHO. World Health Organization","year":"2005"},{"issue":"8","key":"10.1016\/j.vaccine.2026.129180_bb0025","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1002\/jat.3314","article-title":"Dose site reactions and related findings after vaccine administration in safety studies","volume":"36","author":"Baldrick","year":"2016","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.vaccine.2026.129180_bb0090","author":"FDA. Food and Drug Administration"},{"key":"10.1016\/j.vaccine.2026.129180_bb0175","author":"ICH. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use"},{"key":"10.1016\/j.vaccine.2026.129180_bb0050","author":"CHMP. Committee for Medicinal Products for Human Use"},{"key":"10.1016\/j.vaccine.2026.129180_bb0095","author":"FDA. Food and Drug Administration"},{"key":"10.1016\/j.vaccine.2026.129180_bb0180","author":"ICMRA"},{"key":"10.1016\/j.vaccine.2026.129180_bb0185","author":"ICMRA"},{"key":"10.1016\/j.vaccine.2026.129180_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2023.105438","article-title":"Evaluation of non-clinical toxicity studies of COVID-19 vaccines","volume":"142","author":"Schilder","year":"2023","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.vaccine.2026.129180_bb0160","author":"Hastings"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129180_bb0295","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/10915818241293371","article-title":"Are repeat-dose toxicity studies informative for safety assessment of vaccine candidates? A survey of vaccine developers","volume":"44","author":"Rohde","year":"2024","journal-title":"Int J Toxicol"},{"issue":"9","key":"10.1016\/j.vaccine.2026.129180_bb0080","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","article-title":"The 60-year evolution of lipid nanoparticles for nucleic acid delivery","volume":"23","author":"Cullis","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129180_bb0150","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1186\/s12951-024-02972-w","article-title":"Navigating the intricate in-vivo journey of lipid nanoparticles tailored for the targeted delivery of RNA therapeutics: a quality-by-design approach","volume":"22","author":"Haghighi","year":"2024","journal-title":"J Nanobiotechnol"},{"issue":"2\u20133","key":"10.1016\/j.vaccine.2026.129180_bb0235","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","article-title":"Solid lipid nanoparticles production, characterization and applications","volume":"47","author":"Mehnert","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2026.129180_bb0325","first-page":"23","article-title":"Lipid nanoparticles: production, characterization and stability","author":"Shah","year":"2014","journal-title":"SpringerBriefs Pharm Sci Drug Dev"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129180_bb0205","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in technologies for therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129180_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27041372","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129180_bb0255","doi-asserted-by":"crossref","first-page":"305","DOI":"10.15171\/apb.2015.043","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: structure, preparation and application","volume":"5","author":"Naseri","year":"2015","journal-title":"Adv Pharm Bull"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129180_bb0155","doi-asserted-by":"crossref","first-page":"7233","DOI":"10.1038\/s41467-021-27493-0","article-title":"An ionizable lipid toolbox for RNA delivery","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129180_bb0170","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat Rev Mater"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129180_bb0230","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12275-6","article-title":"Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells","volume":"10","author":"Maugeri","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129180_bb0340","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11095-022-03460-2","article-title":"Structure and function of cationic and ionizable lipids for nucleic acid delivery","volume":"40","author":"Sun","year":"2023","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2026.129180_bb0190","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"10.1016\/j.vaccine.2026.129180_bb0020","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ymthe.2017.03.035","article-title":"Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses","volume":"25","author":"Bahl","year":"2017","journal-title":"Mol Ther"},{"issue":"25","key":"10.1016\/j.vaccine.2026.129180_bb0105","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129180_bb0125","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nbt.2612","article-title":"Image-based analysis of lipid nanoparticle\u2013mediated siRNA delivery, intracellular trafficking and endosomal escape","volume":"31","author":"Gilleron","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129180_bb0265","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202110137","article-title":"Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale","volume":"221","author":"Paramasivam","year":"2021","journal-title":"J Cell Biol"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129180_bb0220","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.1002\/anie.202013927","article-title":"A systematic study of unsaturation in lipid nanoparticles leads to improved mRNA transfection in vivo","volume":"60","author":"Lee","year":"2021","journal-title":"Angew Chem Int Ed"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129180_bb0320","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nbt.1602","article-title":"Rational design of cationic lipids for siRNA delivery","volume":"28","author":"Semple","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2026.129180_bb0135","series-title":"Vaccines","first-page":"44","article-title":"Vaccine manufacturing","author":"Gomez","year":"2013"},{"key":"10.1016\/j.vaccine.2026.129180_bb0365","author":"WHO. World Health Organization"},{"issue":"18","key":"10.1016\/j.vaccine.2026.129180_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21186582","article-title":"MRNA vaccine era\u2014mechanisms, drug platform and clinical prospection","volume":"21","author":"Xu","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"16","key":"10.1016\/j.vaccine.2026.129180_bb0300","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2026.129180_bb0005","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1080\/1061186X.2018.1527337","article-title":"Liposome: composition, characterisation, preparation, and recent innovation in clinical applications","volume":"27","author":"Ahmed","year":"2019","journal-title":"J Drug Target"},{"key":"10.1016\/j.vaccine.2026.129180_bb0015","article-title":"Exploring the landscape of lipid nanoparticles (LNPs): a comprehensive review of LNPs types and biological sources of lipids","volume":"8","author":"Alfutaimani","year":"2024","journal-title":"Int J Pharm: X"},{"issue":"4","key":"10.1016\/j.vaccine.2026.129180_bb0270","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129180_bb0195","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1016\/j.vaccine.2023.12.031","article-title":"How manufacturing won or lost the COVID-19 vaccine race","volume":"42","author":"King","year":"2024","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129180_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9010003","article-title":"Resources, production scales and time required for producing RNA vaccines for the global pandemic demand","volume":"9","author":"Kis","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2026.129180_bb0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.toxlet.2023.07.011","article-title":"Off target toxicities and links with physicochemical properties of medicinal products, including antibiotics, oligonucleotides, lipid nanoparticles (with cationic and\/or anionic charges). Data review suggests an emerging pattern","volume":"384","author":"Gould","year":"2023","journal-title":"Toxicol Lett"},{"key":"10.1016\/j.vaccine.2026.129180_bb0375","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jconrel.2019.05.030","article-title":"Liposome and immune system interplay: challenges and potentials","volume":"305","author":"Zahednezhad","year":"2019","journal-title":"J Control Release"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129180_bb0345","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3390\/vaccines12101148","article-title":"Recent advances in lipid nanoparticles and their safety concerns for mRNA delivery","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129180_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129180_bb0010","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"issue":"13","key":"10.1016\/j.vaccine.2026.129180_b9000","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.vaccine.2015.01.073","article-title":"Committee IHV and ASP Safety of vaccine adjuvants: focus on autoimmunity","volume":"33","author":"van der Laan","year":"2015","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129180_bb0060","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cmi.2023.12.010","article-title":"Comparative safety analysis of mRNA and adenoviral vector COVID-19 vaccines: a nationwide cohort study using an emulated target trial approach","volume":"30","author":"Choi","year":"2024","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2026.129180_bb0070","article-title":"Vaccine safety issues at the turn of the 21st century","volume":"6","author":"Conklin","year":"2021","journal-title":"BMJ Glob Health"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129180_bb0045","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41541-024-00893-1","article-title":"Myocarditis associated with COVID-19 vaccination","volume":"9","author":"Buoninfante","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"27","key":"10.1016\/j.vaccine.2026.129180_bb0115","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory Committee on immunization practices \u2014 United States, June 2021","volume":"70","author":"Gargano","year":"2021","journal-title":"Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129180_bb0280","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.hlc.2021.07.011","article-title":"Myocarditis, pericarditis and cardiomyopathy after COVID-19 vaccination \u2606","volume":"30","author":"Pepe","year":"2021","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.vaccine.2026.129180_bb0285","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-069445","article-title":"Incidence, risk factors, natural history, and hypothesized mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review","volume":"378","author":"Pillay","year":"2022","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129180_bb0290","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11020417","article-title":"Toxicological assessments of a pandemic COVID-19 vaccine\u2014demonstrating the suitability of a platform approach for mRNA vaccines","volume":"11","author":"Rohde","year":"2023","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129180_bb0085","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/10915818221138781","article-title":"Nonclinical safety assessment of lipid nanoparticle-and emulsion-based self-amplifying mRNA vaccines in rats","volume":"42","author":"Donahue","year":"2023","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.vaccine.2026.129180_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2022.105189","article-title":"Development of COVID-19 therapies: nonclinical testing considerations","volume":"132","author":"Baldrick","year":"2022","journal-title":"Regul Toxicol Pharmacol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129180_bb0165","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-00980-3","article-title":"Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines","volume":"9","author":"Hauguel","year":"2024","journal-title":"npj Vaccines"},{"key":"10.1016\/j.vaccine.2026.129180_bb0360","series-title":"Evaluation of the quality, safety and efficacy of messenger RNA vaccines for the prevention of infectious diseases: regulatory considerations","author":"WHO. World Health Organization","year":"2022"},{"key":"10.1016\/j.vaccine.2026.129180_bb0140","series-title":"Pathology of the laboratory rabbit","first-page":"19","article-title":"Future use of rabbits in safety assessment regulatory studies","author":"Gould","year":"2026"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129180_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101518","article-title":"Rational design of lipid nanoparticles for enabling gene therapies","volume":"33","author":"Brimacombe","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"5","key":"10.1016\/j.vaccine.2026.129180_bb0210","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1021\/acsnano.8b01516","article-title":"On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA","volume":"12","author":"Kulkarni","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.vaccine.2026.129180_bb0065","author":"Clinicaltrials.Gov"},{"issue":"11","key":"10.1016\/j.vaccine.2026.129180_bb0275","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41573-024-01042-y","article-title":"mRNA vaccines for infectious diseases \u2014 advances, challenges and opportunities","volume":"23","author":"Pardi","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"7993","key":"10.1016\/j.vaccine.2026.129180_bb0245","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","article-title":"N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting","volume":"625","author":"Mulroney","year":"2024","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.vaccine.2026.129180_bb0040","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/jat.4548","article-title":"Nonclinical safety assessment of an mRNA Covid-19 vaccine candidate following repeated administrations and biodistribution","volume":"44","author":"Broudic","year":"2024","journal-title":"J Appl Toxicol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129180_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-07661-8","article-title":"Efficacy and safety of a novel multivalent mRNA vaccine against SARS-CoV-2 in experimental animals","volume":"15","author":"Min","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.129180_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.882972","article-title":"Vaccine-associated enhanced disease and pathogenic human coronaviruses","volume":"13","author":"Gartlan","year":"2022","journal-title":"Front Immunol"},{"issue":"22","key":"10.1016\/j.vaccine.2026.129180_bb0250","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1016\/j.vaccine.2021.01.055","article-title":"Vaccine-associated enhanced disease: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"39","author":"Munoz","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129180_bb0055","author":"CHMP. Committee for Medicinal Products for Human Use"},{"key":"10.1016\/j.vaccine.2026.129180_bb0100","author":"FDA. Food and Drug Administration"},{"key":"10.1016\/j.vaccine.2026.129180_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2026.128394","article-title":"Evidence-based assessment of safety and mechanistic questions related to mRNA COVID-19 vaccines","volume":"77","author":"Sohn","year":"2026","journal-title":"Vaccine"},{"issue":"10441","key":"10.1016\/j.vaccine.2026.129180_bb0330","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","article-title":"Contribution of vaccination to improved survival and health: modelling 50 years of the expanded programme on immunization","volume":"403","author":"Shattock","year":"2024","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.vaccine.2026.129180_bb0110","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1016\/j.vaccine.2011.04.046","article-title":"The safety evaluation of adjuvants during vaccine development: the AS04 experience","volume":"29","author":"Gar\u00e7on","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129180_bb0130","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jat.3329","article-title":"Non-clinical safety assessment of single and repeated administration of gE\/AS01 zoster vaccine in rabbits","volume":"37","author":"Giordano","year":"2017","journal-title":"J Appl Toxicol"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129180_bb0310","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.yrtph.2015.06.003","article-title":"Effects of adjuvant systems on the cardiovascular and respiratory functions in telemetered conscious dogs and anaesthetised rats","volume":"73","author":"Segal","year":"2015","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.vaccine.2026.129180_bb0315","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.reprotox.2017.03.015","article-title":"Intramuscularly administered herpes zoster subunit vaccine has no effects on fertility, pre- and post-natal development in sprague-dawley rats","volume":"69","author":"Segal","year":"2017","journal-title":"Reprod Toxicol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:22:22Z","timestamp":1791908542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":75,"alternative-id":["S0264410X26009898"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129180","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Summary of 2025 Society of Toxicology Workshop \u201cVaccine Toxicology in the Post-COVID Era\u201d","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"129180"}}